one could only hope Jake, but any trial with CytoDyn would depend on the partner to put up all the cash and do all the leg work while CytoDyn only puts up leronlimab.

let me refer to MLAB's post On Partnering

He writes:

Quote:

---

" In general the way a partnership works is CYDY will stay intact as they are. The Big pharma partner will pay or fund part of the development of the drug for a specific indication. If CYDY had a very robust infrastructure, which we do not, CYDY would conduct the studies required for that indication using the partner's money. But, CYDY is poor and has almost zero infrastructure. All CYDY has is the main asset LL, and provocative data. Therefore, CYDY will ask for money to help keep CYDY afloat and the Pharma partner will run the studies themselves or thru an agreed upon third party CRO, plus the partner will also receive future considerations if the trial is positive. What future considerations: The right to continue studying LL in future trials and if LL eventually gets FDA approval the partner will receive the vast majority of the revenue and CYDY will get royalties . This is VERY simple explanation, but limited space on these boards precludes further explanation "

---

So, in the end, where does that leave CytoDyn for that indication? The recipient of Royalties?